ArticleFrontiers in microbiology2026
Complete genome sequencing of
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Whole-genome sequencing ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: As a free aglycone with higher bioavailability and pharmacological activity, liquiritigenin can be obtained from liquiritin (liquiritigenin-4'-O- Methods: In this study, the complete genome of Result: The genome size of this strain was 3,257,491 bp with a GC content of 44.58%, presenting as a circular chromosome. It contained 3,081 CDS, 67 tRNAs, 1 tmRNA, and 16 rRNAs, together with a circular plasmid of 53,560 bp in size and 38.68% GC content. The purified ApgA with a molecular weight of 53.4 kDa was obtained through heterologous expression. Optimization of enzymatic reaction conditions demonstrated that the conversion rate of liquiritin reached 99% after incubating ApgA with 0.1% liquiritin for 4 h. Discussion: This study clarified the genomic characteristics of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.